Schubert & CO Biocryst Pharmaceuticals Inc Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$7.94 - $11.84 $103 - $153	-13 Reduced 29.55%	31 $0
Q4 2022 Jan 31, 2023	SELL	$10.5 - $14.2 $94 - $127	-9 Reduced 16.98%	44 $0
Q3 2022 Oct 21, 2022	BUY	$10.79 - $14.81 $172 - $236	16 Added 43.24%	53 $1,000
Q2 2022 Aug 01, 2022	BUY	$7.89 - $17.88 $173 - $393	22 Added 146.67%	37 $0
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $127 - $217	11 Added 275.0%	15 $0
Q4 2021 Jan 28, 2022	BUY	$11.18 - $15.46 $44 - $61	4 New	4 $0

279

169M

930K

1.03M

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.68B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.